Olverembatinib, an investigational multikinase inhibitor (approved in China for CML), inhibits Src-family kinases (e.g., Lyn, ...

The research on bone-marrow transplantation mirrors the arc of many medical advancements. I was one of the early ...

A healthy 27-year-old from Solihull was shocked when he was diagnosed with a rare form of leukaemia. Charlie was rushed to ...

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose and ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million ...

SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance immunotherapy in AML. ・Sellas is approaching a Phase 3 Regal survival readout, a ...

An analysis of the 2025 AHA/ACC hypertension guidelines found that under the new guidelines, about 11% of adults ages 65 to 79 with stage I hypertension would no longer qualify for blood pressure ...